ARTICLE | Clinical News
Humira adalimumab: Phase III; marketed for rheumatoid arthritis (RA)
October 6, 2003 7:00 AM UTC
ABT started a second placebo-controlled international Phase III trial in an undisclosed number of patients (see BioCentury, Sept. 9, 2002). Humira was developed with Cambridge Antibody Technology Gro...